文献速递MDS 与骨髓增殖性肿瘤

他汀类药物使用与骨髓增殖性肿瘤风险:一项丹麦全国性病例对照研究

Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study.
PubMed 文献 · Blood Adv · 2023-01-01

该研究基于丹麦全国登记数据,纳入2010至2018年确诊的3816例骨髓增殖性肿瘤(MPN)患者和19080名年龄性别匹配的对照,评估他汀使用与MPN风险的关联。结果显示他汀使用者MPN风险显著降低(aOR 0.87),长期使用(≥5年)风险更低(aOR 0.72),呈剂量依赖关系。

要点

  • 他汀使用者MPN风险降低,完全校正OR为0.87(95%CI 0.80-0.96)。
  • 长期使用他汀(≥5年)者MPN风险更低,aOR为0.72(95%CI 0.64-0.81)。
  • 他汀使用与MPN风险降低的关联呈剂量依赖关系,且在不同性别、年龄和MPN亚型中一致。

核心结论

  • 他汀使用者被诊断为MPN的比值显著降低,提示他汀可能具有癌症预防作用。
  • 本研究为回顾性研究,无法进行因果推断。

研究设计与样本

  • 采用丹麦全国人口登记数据进行巢式全国性病例对照研究。
  • 病例为2010至2018年丹麦国家慢性髓系肿瘤登记中确诊的MPN患者,共3816例。
  • 对照为按年龄和性别匹配的19080名人群对照(5:1),采用发病率密度抽样。
  • 他汀使用信息来自丹麦国家处方登记。
  • 关联估计采用年龄和性别校正的OR以及完全校正的aOR(校正预设混杂因素)。

主要发现

  • 病例中34.9%曾使用他汀,对照中33.5%曾使用他汀,MPN的OR为1.07(95%CI 0.99-1.16),aOR为0.87(95%CI 0.80-0.96)。
  • 病例中17.2%为长期使用者(≥5年),对照中19.0%为长期使用者,MPN的OR为0.90(95%CI 0.81-1.00),aOR为0.72(95%CI 0.64-0.81)。
  • 他汀累积使用时间的效应分析显示剂量依赖反应。
  • 该关联在性别、年龄和MPN亚组以及不同他汀类型中一致。

局限性

  • 本研究为回顾性研究,无法进行因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous studies have indicated a possible cancer-protective effect of statins in solid cancers; however, this has never been investigated in myeloproliferative neoplasms (MPNs). We aimed to investigate the association between statin use and the risk of MPNs in a nested nationwide case-control study, using Danish national population registries. Information on statin use was obtained from the Danish National Prescription Registry, and patients diagnosed with MPNs between 2010 and 2018 were identified from the Danish National Chronic Myeloid Neoplasia Registry. The association between statin use and MPNs was estimated using age- and sex-adjusted odds ratios (ORs) and fully adjusted ORs (aORs), adjusting for prespecified confounders. The study population included 3816 cases with MPNs and 19 080 population controls (5:1) matched for age and sex using incidence density sampling. Overall, 34.9% of the cases and 33.5% of the controls ever used statins, resulting in an OR for MPN of 1.07 (95% confidence interval [CI], 0.99-1.16) and an aOR of 0.87 (95% CI, 0.80-0.96), respectively. 17.2% were categorized as long-term users (≥5 years) among the cases compared with 19.0% among controls, yielding an OR for MPN of 0.90 (95% CI, 0.81-1.00) and an aOR of 0.72 (95% CI, 0.64-0.81). Analysis of the effect of the cumulative duration of statin use revealed a dose-dependent response, and the association was consistent for sex, age, and MPN subgroups and across different statin types. Statin users were associated with significantly lower odds of being diagnosed with an MPN, indicating a possible cancer-preventive effect of statins. The retrospective of this study precludes causal inferences.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tuyet Kristensen D, Kisbye Øvlisen A, Hjort Kyneb Jakobsen L, et al. Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study. Blood Adv. 2023. PMID: 36877642. doi:10.1182/bloodadvances.2023009784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。